欧洲四种COVID-19疫苗不良药物反应比较:异常部位血栓形成
该观察性研究基于EudraVigilance数据库2021年1月1日至7月30日数据,评估欧洲四种COVID-19疫苗的脑静脉血栓(CVT)报告率。结果显示CVT报告率从Tozinameran的1.92/百万接种日至CHADOX1 NCOV-19的21.60/百万接种日不等,四种疫苗均伴血小板减少,且观察值与预期值比值均大于1。
要点
- 四种疫苗CVT报告率:Tozinameran 1.92、CX-024414 5.63、CHADOX1 NCOV-19 21.60、AD26.COV2.S 11.48每百万接种日。
- CVT在四种疫苗中均与血小板减少同时出现,观察值与预期值比值均大于1。
- 尽管EMA仅对CHADOX1 NCOV-19和AD26.COV2.S发出警报,Tozinameran和CX-024414也并发CVT但程度较轻。
核心结论
- EudraVigilance数据强化了COVID-19疫苗接种后CVT的个案发现。
- 四种疫苗均与CVT相关,腺病毒载体疫苗报告率较高。
研究设计与样本
- 观察性研究,评估欧洲四种授权COVID-19疫苗的CVT报告率。
- 数据来自EudraVigilance数据库2021年1月1日至2021年7月30日。
- CVT报告率以每百万个体接种日表示并计算95%置信区间,并进行观察值与预期值分析。
主要发现
- CVT每百万接种日报告率:Tozinameran 1.92(95% CI 1.71-2.12)。
- CX-024414为5.63(95% CI 4.74-6.64)。
- CHADOX1 NCOV-19为21.60(95% CI 20.16-23.11)。
- AD26.COV2.S为11.48(95% CI 9.57-13.67)。
- 四种疫苗的CVT均伴随血小板减少,观察值与预期值比值均大于1。
关键数值与推荐
- CVT报告率以每百万个体接种日表示,附95%置信区间。
- 观察值与预期值分析显示四种疫苗比值均大于1(最低和最高CVT背景发病率下)。
临床怎么用
- 临床应警惕所有四种COVID-19疫苗接种后CVT可能,尤其腺病毒载体疫苗。
- CVT伴血小板减少时应考虑疫苗相关不良反应。
局限性
- 研究基于自发报告数据库,可能存在报告偏倚。
- 未报告样本量、P值等详细统计信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world experience with adenoviral vector vaccines against COVID-19 raised some safety concerns. Cases of cerebral vein thrombosis (CVT) associated with thrombocytopenia have been observed after the first dose of the adenoviral vector vaccines CHADOX1 NCOV-19 and AD26.COV2.S. OBJECTIVES: To assess the reporting rate of CVT as adverse drug reaction (ADR) for the COVID-19 vaccines authorized in Europe. PATIENTS AND METHODS: This observational study assessed the CVT reporting rate attributed to four COVID-19 vaccines authorized in Europe, namely Tozinameran (Pfizer-Biontech), CX-024414 (Moderna), CHADOX1 NCOV-19 (AstraZeneca), and AD26.COV2.S (Janssen). Data on thrombotic ADRs reported on EudraVigilance database between January 1, 2021 and July 30, 2021, were collected. ADRs referring to CVT were identified. The reporting rate of CVT was expressed as 1 million individual vaccinated-days with 95% confidence interval. Finally, an observed-to-expected (OE) analysis was performed. RESULTS: The reporting rate of CVT per 1 million person vaccinated-days was 1.92 (95% confidence interval [CI], 1.71-2.12) for Tozinameran, 5.63 (95% CI, 4.74-6.64) for CX-024414, 21.60 (95% CI, 20.16-23.11) for CHADOX1 NCOV-19, and 11.48 (95% CI, 9.57-13.67) for AD26.COV2.S. CVT occurred alongside thrombocytopenia for the four vaccines. The OE ratio was greater than one for all four vaccines, both with the lowest and the highest CVT background incidence. CONCLUSIONS: This report on EudraVigilance data strengthens anecdotal findings on CVT following COVID-19 vaccinations. Although the European Medicines Agency released an alert only for CHADOX1 NCOV-19 and AD26.COV2.S, Tozinameran and CX-024414 also are complicated by CVT, albeit to lesser extent.
引用
- Abbattista M, Martinelli I, Peyvandi F, et al. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. J Thromb Haemost. 2021. PMID: 34375510. doi:10.1111/jth.15493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。